Business · 15/03/2004Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for FABRAZYME Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for FABRAZYME, a human biological product, in response to a patent extension application submitted to the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →